Analysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Price Target at $79.00

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned a consensus recommendation of “Buy” from the ten research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $79.78.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday. They set an “overweight” rating and a $85.00 price target on the stock. Leerink Partners assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Finally, Guggenheim boosted their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th.

ANI Pharmaceuticals Trading Up 1.7 %

ANI Pharmaceuticals stock opened at $62.49 on Wednesday. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a market cap of $1.36 billion, a P/E ratio of -113.62 and a beta of 0.62. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The business has a 50-day simple moving average of $58.26 and a two-hundred day simple moving average of $58.13.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,700 shares of company stock valued at $610,201. 12.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of ANI Pharmaceuticals by 41.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock valued at $2,648,000 after acquiring an additional 13,948 shares during the last quarter. Stonepine Capital Management LLC purchased a new stake in ANI Pharmaceuticals during the fourth quarter valued at $1,128,000. Rafferty Asset Management LLC bought a new position in ANI Pharmaceuticals during the fourth quarter valued at $200,000. ProShare Advisors LLC grew its stake in shares of ANI Pharmaceuticals by 29.0% in the 4th quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company’s stock worth $361,000 after buying an additional 1,469 shares in the last quarter. Finally, Nomura Holdings Inc. increased its holdings in shares of ANI Pharmaceuticals by 1.5% in the 4th quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company’s stock worth $11,823,000 after buying an additional 3,255 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.